Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. ADC Therapeutics SA (ADCT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
ADC Therapeutics SA is a member of our Medical group, which includes 891 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ADC Therapeutics SA is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ADCT's full-year earnings has moved 34.3% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that ADCT has returned about 9.4% since the start of the calendar year. In comparison, Medical companies have returned an average of -5.1%. This means that ADC Therapeutics SA is performing better than its sector in terms of year-to-date returns.
Biogen Inc. (BIIB) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 1.7%.
For Biogen Inc., the consensus EPS estimate for the current year has increased 4.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, ADC Therapeutics SA is a member of the Medical - Biomedical and Genetics industry, which includes 436 individual companies and currently sits at #95 in the Zacks Industry Rank. This group has gained an average of 3.1% so far this year, so ADCT is performing better in this area. Biogen Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on ADC Therapeutics SA and Biogen Inc. as they attempt to continue their solid performance.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADC Therapeutics SA (ADCT): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).